Novo Nordisk remains a cautious buy as it faces pressure on adjusted sales and EBIT in Q1 2026 but raised its guidance due to strong uptake of its Wegovy pill. The stock trades at a historically low price-to-earnings ratio of 12.5 times trailing twelve months, indicating market pessimism despite potential growth and multiple expansion after 2026. Competitive risks from Eli Lilly and generics in India and China continue, but Novo Nordisk's higher-dose semaglutide and leading diabetes franchise support its investment appeal. The analyst maintains a Buy rating, seeing an attractive risk-reward balance with expected growth resumption post-2026 reset.
Novo Resources Corp has regained full control of the Egina Gold Project in Western Australia's Pilbara region after Northern Star Resources withdrew from their earn-in agreement. Northern Star decided not to proceed with the additional A$18 million e...
Novo Nordisk has initiated a share repurchase programme worth up to DKK 15 billion, starting from February 4, 2026, and running for 12 months. As of May 22, 2026, the company has repurchased over 17 million B shares at an average price of DKK 262.22 ...
Novo Nordisk's POSEIDON study of 18,904 patients across 18 countries found that 40% of people with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or heart failure have cardiovascular inflammation. This inflammation, mea...
The global Bioprocess Automation Software market, valued at $1.67 billion in 2025, is projected to grow to $6.19 billion by 2035 at a 14% CAGR. This growth is fueled by the increasing demand for personalized medicine, flexible manufacturing processes...
